Home | Privacy | Contact    

Health Information About Carcinoid Tumors


Carcinoid tumors - MayoClinic.com
http://www.mayoclinic.com/health/carcinoid-tumors/DS00834 Carcinoid tumors — Comprehensive overview covers symptoms, diagnosis, treatment of these rare, slow-growing cancerous tumors. more...
Carcinoid - Wikipedia, the free encyclopedia
http://en.wikipedia.org/wiki/Carcinoid Carcinoid tumors are the most common malignant tumor of the appendix, but they are most commonly associated with the small intestine, and they can also be found in the rectum and ... more...
The Carcinoid Cancer Foundation, Inc.
http://www.carcinoid.org/ Serving the National and International Carcinoid/NeuroEndocrine Tumor (NET) community since 1968 more...
Carcinoid Tumors: Hormonal Disorders: Merck Manual Home Edition
http://www.merck.com/mmhe/sec13/ch168/ch168a.html Carcinoid tumors are noncancerous (benign) or cancerous (malignant) growths that sometimes produce excessive amounts of hormonelike substances, resulting in the carcinoid syndrome. more...
Carcinoid Tumor: eMedicine Pediatrics: General Medicine
http://emedicine.medscape.com/article/986050-overview Overview: Origin and general involvement and presentationCarcinoid tumors are derived from primitive stem cells in the gut wall but can be seen in other organs,1 including the ... more...



Carcinoid Tumors News


carcinoid tumors - Bing News
ImmunoGen, Inc. Announces Orphan Drug Designation Granted to IMGN901 ... - Businesswire.com
“IMGN901 has shown promising activity among the small number of MCC patients treated to date, suggesting this is a potential registration path for the compound” “IMGN901 has shown promising activity among the small number of MCC patients ... read more...
Lexicon Pharma says it will sell $95M in stock - BusinessWeek
Biotechnology company Lexicon Pharmaceuticals Inc. said Monday it plans to raise money by selling $95 million in stock to the public. Lexicon has not yet announced a sale price for the shares. The underwriters of the offering will have a 30-day ... read more...